

Ghana Support for Yellow Fever Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Ghana				
2. Grant number: 1719-GHA-06b-X				
3. Date of Decision Letter: 21 December 2017				
4. Date of the Partnership Framework Agreement: 11 July 2014				
5. Programme title: NVS, Yellow Fever Routine				
6. Vaccine type: Yellow Fever				
7. Requested product presentation and formulation of vaccine: Yellow Fever, 10 dose(s) per vial, LYOPHILISED				
8. Programme duration¹: 2001 - 2019				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)				
	2001-2017	2018	2019	Total ²
Programme Budget (US\$)	US\$11,173,507 ³	US\$886,500	US\$856,500	US\$12,916,507
10. Vaccine introduction grant (in US\$): Not applicable				
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴				
Type of supplies to be purchased with Gavi funds in each year	2001-2017	2018		
Number of Yellow Fever vaccines doses		770,700		
Annual Amounts (US\$)	US\$11,173,507 ⁵	US\$886,500		

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p>12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.</p>																							
<p>13. Self-procurement: Not applicable</p>																							
<p>14. Co-financing obligations: Reference code: 1719-GHA-06b-X-C According to the Co-Financing Policy, the Country falls within the Preparatory transition group as of 1 January 2018. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2018</th> <th>2019</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>259,200</td> <td>728,100</td> </tr> <tr> <td>Number of AD syringes</td> <td>186,700</td> <td></td> </tr> <tr> <td>Number of re-constitution syringes</td> <td>28,600</td> <td></td> </tr> <tr> <td>Number of safety boxes</td> <td>2,375</td> <td></td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$ 277,270</td> <td></td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>US\$308,000</td> <td>US\$869,000</td> </tr> </tbody> </table>			Type of supplies to be purchased with Country funds in each year	2018	2019	Number of vaccine doses	259,200	728,100	Number of AD syringes	186,700		Number of re-constitution syringes	28,600		Number of safety boxes	2,375		Value of vaccine doses (US\$)	US\$ 277,270		Total co-financing payments (US\$) (including freight)	US\$308,000	US\$869,000
Type of supplies to be purchased with Country funds in each year	2018	2019																					
Number of vaccine doses	259,200	728,100																					
Number of AD syringes	186,700																						
Number of re-constitution syringes	28,600																						
Number of safety boxes	2,375																						
Value of vaccine doses (US\$)	US\$ 277,270																						
Total co-financing payments (US\$) (including freight)	US\$308,000	US\$869,000																					
<p>15. Operational support for campaigns: Not applicable</p>																							
<p>16. Additional reporting requirements:</p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>May</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>			Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat															
Reports and other information	Due dates																						
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May																						
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat																						
<p>17. Financial clarifications: Not applicable</p>																							

18. Other conditions: There is currently a global shortage in the supply of yellow fever vaccines. The number of doses and presentation are subject to availability. Gavi will inform the Government as soon as possible of any changes in doses and/or presentation from what has been communicated to the Ghana.

The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.

Signed by,

Hind A. Khatib

On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
21 December 2017